The lineup for the Royal Society of Chemistry’s 5th “Artificial Intelligence in Chemistry” Symposium (Thursday-Friday, 1st-2nd September 2022) is now complete for both oral and poster presentations. It really is a fantastic selection of topics and speakers and it is clear this event is now a highlight of the scientific calendar. Our very own Prof. Charlotte M. Deane, MBE will be giving a keynote.
Catching up on the literature is one of the highlights of my job as a scientist. True, sometimes you can be overwhelmed by the amount of information you don’t have; or wonder if we really need another paper showing that protein-ligand scoring functions don’t work. And yet, sometimes you find excellent research that you can’t but regard with a mixture of awe and envy. At a recent group meeting, I discussed one such paper from the research group of Aviv Regev at MIT, where the authors perform an impressive combination of computation and experiment to consider some basic questions in gene regulation and evolution. Here is why I think it’s excellent.
The authors are interested in promoters, small sequences of DNA that precede genes, which are known to regulate how frequently their partners will be expressed. In short, these promoters are binding sites for transcription factors, a family of proteins that in turn recruit RNA polymerase to transcribe DNA to RNA. In turn, albeit not directly, the rate of gene transcription determines the rate at which a protein is produced. If this sounds simple, however, that is where our understanding stops. The human genome encodes some 1.6k different transcription factors (~6-7% of protein-coding genes) and their underworkings are still not well-understood.
Yep, it is very well known that the sugar coating (aka glycosylation) of viruses makes them invisible to the immune system, a strategy so effective that like in the case of HIV, whose spike is almost entirely covered by glycans, makes it so difficult to target by the human immune system.
Unsurprisingly, coronaviruses such as SARS, MERS, and SARS-CoV-1(2) not only benefit from this evolutionary strategy but there is evidence now that sugars provide stability to their spikes to be effective binders by glueing the spike chains, hence making them infectious.
This is the major finding of this paper that introduces very interesting results from all-atom MD simulations of a fully glycosylated model of the SARS-CoV-2 spike protein embedded in a realistic viral membrane. Researchers aimed to look into the stability of the protein spike (A, B, and C) chains in the “open” and “closed” conformation and how these changed upon key residue mutations to test how glycans sitting in the inter-chain space affect stability. It also aimed at quantifying glycans’ shielding effect from molecules ranging from 2 to 15 Angstroms, i.e., from small-sized to peptide- and antibody-sized molecules.
I was planning on doing a blog post about some cool random deep learning paper that I have read in the last year or so. However, I keep finding that someone else has already written a way better blog post than what I could write. Instead I have decided to write a very brief summary of some hot ideas and then provide a link to some other page where someone describes it way better than me.
Anyways, the hypothesis says the following: “Dense, randomly-initialized, feed-forward networks contain subnetworks (winning tickets) that—when trained in isolation—reach test accuracy comparable to the original network in a similar number of iterations.” In their analogy, the random initialization of a models weights is treated like a lottery, where some combination of a subset of these weight is already pretty close to the network you want to train (winning ticket). For a better description and a summary of advances in this field I would recommend this blog post.
SAM: Sharpness aware minimization
The key idea here has to do with finding the best optimizer to train a model capable of generalization. According to this paper, a model that has converged to a sharp minima will be less likely to generalize than one that has converged to a flatter minima. They show the following plot to provide an intuition of why this may be the case.
Recently, University College London Hospitals (UCLH) received a “Specials License” to allow the treatment of six patients suffering from Creutzfeldt–Jakob Disease (CJD), by way of a novel antibody known as PRN100. The results of this treatment have now been published in The Lancet.
There is currently no cure for CJD, yet over 100 people per year develop it either spontaneously or through external means including (but not limited to) growth hormones, cataract surgery or infected neurosurgical implements [1]. “There is no UK legislation which implements a compassionate use programme as set out in Article 83 of the relevant EU regulation. But the UK has implemented an exemption process known as the “Specials” in light of the requirement to be able to deal with special needs.” [2]
As there is no known cure, the request for use of PRN100 was put before the court as in Law“Some treatment decisions are so serious that the court has to make them.”
With many tours (Farcical and otherwise) restricted due to Covid, 2022 celebrated the resurrection of OPIG’s glorious Tour de Farce. This year’s route was nine miles and an unusually conservative four pubs.
After listening to Lewis’ conference prep talk, we left the Statistics Department around 5pm for a leisurely trundle through Mesopotamia, The Oxford Psychopath, Old Marston and out to our first rest stop, The Victoria.
Finding a way to express the similarity of irregular and discrete molecular graphs to enable quantitative algorithmic reasoning in chemical space is a fundamental problem in data-driven small molecule drug discovery.
Virtually all algorithms that are widely and successfully used in this setting boil down to extracting and comparing (multi-)sets of subgraphs, differing only in the space of substructures they consider and the extent to which they are able to adapt to specific downstream applications.
A large body of recent work has explored approaches centred around graph neural networks (GNNs), which can often maximise both of these considerations. However, the subgraph-derived embeddings learned by these algorithms may not always perform well beyond the specific datasets they are trained on and for many generic or resource-constrained applications more traditional “non-parametric” topological fingerprints may still be a viable and often preferable choice .
This blog post gives an overview of the topological fingerprint algorithms implemented in RDKit. In general, they count the occurrences of a certain family of subgraphs in a given molecule and then represent this set/multiset as a bit/count vector, which can be compared to other fingerprints with the Jaccard/Dice similarity metric or further processed by other algorithms.
A blog post about reviewing papers and preparing papers for publication.
We start with the following premise: all papers have limitations. There is not a single paper without limitations. A method may not be generally applicable, a result may not be completely justified by the data or a theory may make restrictive assumptions. To cover all limitations would make a paper infinitely long, so we must stop somewhere.
A lot of limitations fall into the following scenario. The results or methods are presented but they could have extended them in some way. Suppose, we obtain results on a particular cell type using an immortalized cell-line. Are the results still true, if we performed the experiments on primary or patient-derived cells? If the signal from the original cells was sufficiently robust then we would hope so. However, we can not be one hundred percent sure. A similar example is a method that can be applied to a certain type of data. It may be possible to extend the method to be applied to other data types. However, this may require some new methodology. I call this flavor of limitations vertical limitations. They are vertical in the sense that they build upon an already developed result in the manuscript. For certain journals, they will require that you tackle vertical limitations by adapting the original idea or method to demonstrate broad appeal or that idea could permeate multiple fields. Most of the time, however, the premise of an approach is not to keep extending it. It works. Leave it alone. Do not ask for more. An idea done well does not need more.
The Oxford Medical Research Council Doctoral Training Partnership (MRC DTP), the program through which my DPhil is funded, hosts an annual Symposium to highlight research being conducted by DTP students and offer insights into the career paths of external speakers.
This year, I was on the committee organising the Symposium and was involved in selecting student presenters, as well as deciding on and inviting external speakers. It was a great experience!
Panel on careers in biotech featuring Loïc Roux, Ochre Bio (centre); Helena Meyer-Berg, Sirion Biotech (centre right); and Claire Shingler, Oxford BioEscalator (right).
Over the past year, I have been working on building a graph-based paratope (antibody binding site) prediction tool – Paragraph. Fortunately, I have had moderate success with this and you can now check out the preprint of this work here.
However, for a long time, I struggled with a highly unstable network, where different random seeds yielded very different results. I believe this instability was largely due to the high class imbalance in my data – only ~10% of all residues in the Fv (variable region of the antibody) belong to the paratope.
I tried many different things in an attempt to stabilise my training, most of which failed. I will share all of these ideas with you though – successful or not – as what works for one person/network is never guaranteed to work for another. I hope that the below may provide some ideas to try out for others facing similar issues. Where possible, I also provide some example hyperparameter values that could act as sensible starting points.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.
Name
Description
Duration
Cookie Preferences
This cookie is used to store the user's cookie consent preferences.
30 days
These cookies are used for managing login functionality on this website.
Name
Description
Duration
wordpress_logged_in
Used to store logged-in users.
Persistent
wordpress_sec
Used to track the user across multiple sessions.
15 days
wordpress_test_cookie
Used to determine if cookies are enabled.
Session
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Contains information related to marketing campaigns of the user. These are shared with Google AdWords / Google Ads when the Google Ads and Google Analytics accounts are linked together.
90 days
__utma
ID used to identify users and sessions
2 years after last activity
__utmt
Used to monitor number of Google Analytics server requests
10 minutes
__utmb
Used to distinguish new sessions and visits. This cookie is set when the GA.js javascript library is loaded and there is no existing __utmb cookie. The cookie is updated every time data is sent to the Google Analytics server.
30 minutes after last activity
__utmc
Used only with old Urchin versions of Google Analytics and not with GA.js. Was used to distinguish between new sessions and visits at the end of a session.
End of session (browser)
__utmz
Contains information about the traffic source or campaign that directed user to the website. The cookie is set when the GA.js javascript is loaded and updated when data is sent to the Google Anaytics server
6 months after last activity
__utmv
Contains custom information set by the web developer via the _setCustomVar method in Google Analytics. This cookie is updated every time new data is sent to the Google Analytics server.
2 years after last activity
__utmx
Used to determine whether a user is included in an A / B or Multivariate test.
18 months
_ga
ID used to identify users
2 years
_gali
Used by Google Analytics to determine which links on a page are being clicked
30 seconds
_ga_
ID used to identify users
2 years
_gid
ID used to identify users for 24 hours after last activity
24 hours
_gat
Used to monitor number of Google Analytics server requests when using Google Tag Manager
1 minute
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
Name
Description
Duration
_GRECAPTCHA
Google reCAPTCHA sets a necessary cookie (_GRECAPTCHA) when executed for the purpose of providing its risk analysis.